

FIG. 1A








FIG. 1B


Subject 1 Prior nAMD Treatment Experience**FIG. 2A**

Subject 1 OCT Images by Visit**FIG. 2B**


Subject 2 Prior nAMD Treatment Experience**FIG. 2C**


6/20

Subject 2 OCT Images by Visit**FIG. 2D**


Subject 3 Prior nAMD Treatment Experience**FIG. 2E**

8/20


Subject 3 OCT Images by Visit**FIG. 2F**

Subject 4 Prior nAMD Treatment Experience**FIG. 2G**

10/20

Subject 4 OCT Images by Visit**FIG. 2H**

11/20

Subject 5 Prior nAMD Treatment Experience**FIG. 2I**

12/20

Subject 5 OCT Images by Visit






FIG. 2J

Subject 6 Prior nAMD Treatment Experience**FIG. 2K**

14/20

Subject 6 OCT Images by Visit**FIG. 2L**

SUBSTITUTE SHEET (RULE 26)




FIG. 3




FIG. 4

ATGGTCAGCTACTGGGACACCGGGGCTCTGTGTGCGCGCTGCTCAGCTGTCTGC
TTCTCACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTCTGTAGAGATGTA
CAGTGAAATCCCCGAAATTATACACATGACTGAAGGAAGGAGCTCGTCAATTCC
CTGCCGGTTACGTACCTAACATCACTGTTACTTTAAATAAGTTTCCACTTGAC
ACTTTGATCCCTGATGGAAAACGCATATCTGGGACAGTAGAAAAGGGCTTCATC
ATATCAAATGCAACGTACAAAGAAATAGGGCTTCTGACCTGTGAAGCAACAGTC
AATGGGCATTTGTATAAGACAAACTATCTCACACATCGACAAACCAATACAAATC
ATAGATGTGGTTCTGAGTCCGTCTCATGGAAATTGAACATCTGTTGGAGAAAAGC
TTGTCTTAAATTGTACAGCAAGAACTGAACATAATGTGGGGATTGACTTCAACTG
GGAATACCTTCTTCGAAGCATCAGCATAAGAAACTTGTAAACCGAGACCTAAA
AACCAGTCTGGGAGTGAGATGAAGAAATTTTGGACACCTTAACATAAGATGG
TGTAACCCGGAGTGACCAAGGATTGTACACCTGTGCAGCATCCAGTGGGCTGAT
GACCAAGAAAGAACAGCACATTTGTGAGGGTCCATGAAAGGACAAAACCTCACA
CATGCCACCGTGCCAGCACCTGAACCTCCTGGGGACCGTCAGTCTTCTCTT
CCCCCAAAACCCAGGACACCTCATGATCTCCCGGACCCCTGAGGTCACATG
CGTGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAGTTCAACTGGTACGT
GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGGGGAGGAGCAGTACA
ACAGCACGTACCGTGTGGTCAGCGTCTCACCGTCTCCACAAAGCCCTCCAGCCCATCG
ATGGCAAGGAGTACAAGTGCAAGGTCTCCACAAAGCCCTCCAGCCCATCG
AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACACAGGTGTACACC
CTGCCCCCATCCCGGATGAGCTGACCAAGAACAGGTACGCTGACCTGACCTGCTG
GTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG
CCGGAGAAACAATAAGACACCGCTCCCGTGTGACTCCGACGGCTCCTTC
TTCTCTACAGCAAGCTCACCGTGGACAAAGAGCAGGTGGCAGCAGGGGAACGTC
TTCTCATGTCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAAGAGC
CTCTCCCTGTCTCCGGGTAATGA

FIG. 5




FIG. 6

	Subject 1: 44 Weeks Post-AAV2/m6-antibodycp		Subject 2: 40 Weeks Post-AAV2/m6-antibodycp		Subject 3: 36 Weeks Post-AAV2/m6-antibodycp	
Baseline OCT						
Latest OCT						
BCVA Change from Baseline, ETDRS letters	+3		-9		-6	
IVT in 8 months prior to this study, n	5		6		6	
Rescue IVT during this study, n	0		0		0	

FIG. 7A







	Subject 4, 32 Weeks Post-AAV2 / ImB-silbercept		Subject 5, 28 Weeks Post-AAV2 / ImB-silbercept		Subject 6, 28 Weeks Post-AAV2 / ImB-silbercept	
Baseline OCT						
Latest OCT						
BCVA Change from Baseline, ETDRS letters	+5		+1		-3	
IVT in 8 months prior to this study, n	6		6		8	
Rescue IVT in this study, n	0		0		0	

FIG. 7B